Corporate Finance

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.

While Beijing touts economic partnership, its deepening ties with Myanmar's isolated junta raise critical questions about debt, dependency, and regional stability.

Aether Education's expansion reveals a deeper trend in Hong Kong: a high-stakes, privatized system where 'character' is the new competitive credential.

ISS is set to unveil its next strategic chapter. With a focus on North American expansion and operational excellence, what should investors watch for?

With a new strategic funding round, LUMIQ aims to scale its autonomous AI, which makes auditable decisions in minutes, not weeks, for banks and insurers.

Defiance ETFs launches Europe's first memory-focused fund as analysts predict prices could soar 130%, reshaping the entire global technology supply chain.

South Korean brand Lactomedi’s nationwide CVS launch signals a major shift in feminine care, blending K-Beauty innovation with advanced microbiome science.

A landmark partnership between tech platform Evermos and the ILO is tackling high unemployment among Indonesia's vulnerable groups with a powerful new tool: a smartphone.

After a profitable Q1, InnSuites is leveraging its hotel success to explore a reverse merger, clean energy, and a revived hotel services venture.

Align Technology names Exact Sciences veteran Kevin Conroy its next Chairman, a strategic move signaling a new chapter of growth and innovation in digital dentistry.

The Baton Rouge bank's 9% dividend increase is more than a number. It's a strategic signal of financial health and a blueprint for stable growth.

Aura Minerals unveils a huge buyback, signaling deep confidence. But with a sky-high P/E ratio and insider sales, is this a smart move or a risky gamble?

New data reveals a massive revenue gap in entertainment. Ignoring the U.S. Latino market isn't just an oversight—it's a quantifiable business disaster.

Mesa Royalty Trust's suspended June distribution is more than a missed check; it's a stark symptom of deep-seated issues facing an entire investment class.

BCB Bancorp's dividend suspension goes beyond capital preservation. A new CEO is confronting a legacy of high-risk loans in cannabis and small business.

As Quantum Leap Acquisition Corp.’s shares and warrants begin separate trading, the SPAC's experienced team now faces its real test: finding a winner.

Pramaana Labs just raised a massive seed round to solve AI's biggest flaw: its inability to be held accountable. But can mathematical proof truly tame AI?

CosmoFarm hits a $60M run-rate with advanced robotics, but its record growth is set against the backdrop of parent Cosmos Health's 'going concern' warning.

Saul Centers holds its dividend firm, offering a tempting yield. But beneath this surface of stability lies a high payout ratio, forcing investors to ask: Is this a safe harbor or a sign of future strain?

AbbVie's latest dividend increase isn't just good news for investors; it's a window into the pharma giant's strategy for navigating future challenges.